Cerium oxide nanoparticle treatment ameliorates peritonitis-induced diaphragm dysfunction

Shinichi Asano,1,2 Ravikumar Arvapalli,1 Nandini DPK Manne,1,2 Mani Maheshwari,1,3 Bing Ma,1,2 Kevin M Rice,1 Vellaisamy Selvaraj,1,2 Eric R Blough1,3

1Center for Diagnostic Nanosystems, 2Department of Pharmacology, Pharmaceutical Sciences and Research, School of Pharmacy, 3Department of Pharmacology, Physiology and Toxicology, Joan C Edwards School of Medicine, Marshall University, Huntington, WV, USA

Abstract: The severe inflammation observed during sepsis is thought to cause diaphragm dysfunction, which is associated with poor patient prognosis. Cerium oxide (CeO2) nanoparticles have been posited to exhibit anti-inflammatory and antioxidative activities suggesting that these particles may be of potential use for the treatment of inflammatory disorders. To investigate this possibility, Sprague Dawley rats were randomly assigned to the following groups: sham control, CeO2 nanoparticle treatment only (0.5 mg/kg iv), sepsis, and sepsis+CeO2 nanoparticles. Sepsis was induced by the introduction of cecal material (600 mg/kg) directly into the peritoneal cavity. Nanoparticle treatment decreased sepsis-associated impairments in diaphragm contractile (P) function (sham: 25.6±1.6 N/cm² vs CeO2: 23.4±0.8 N/cm², vs Sep: 15.9±1.0 N/cm² vs Sep+CeO2: 20.0±1.0 N/cm², P<0.05). These improvements in diaphragm contractile function were accompanied by a normalization of protein translation signaling (Akt, FOXO-1, and 4EBP1), diminished proteolysis (caspase 8 and ubiquitin levels), and decreased inflammatory signaling (Stat3 and iNOS). Histological analysis suggested that nanoparticle treatment was associated with diminished sarcolemma damage and diminished inflammatory cell infiltration. These data indicate CeO2 nanoparticles may improve diaphragm function in the septic laboratory rat.

Keywords: cerium oxide nanoparticles, anti-inflammatory, nitric oxide, diaphragm

Introduction

The pharmacological application of nanotechnology has become an area of intense interest in recent years, and some have posited that cerium oxide (CeO2) nanoparticles may be uniquely suited for several different types of biomedical applications.1 Ceria is an element of the lanthanide series that when complexed with oxygen allows it to effectively transition between oxidative states (Ce3+ and Ce4+) where it can participate in redox cycling and function as antioxidant.2 Other data have suggested that CeO2 nanoparticles are thought to be largely nontoxic under physiologic conditions,3 that they appear to be well tolerated in vivo,4 that may also exhibit antimicrobial effects,5 and that they may be useful for the treatment of disease states characterized by elevations in cellular reactive oxygen species.6 Consistent with these data, recent studies have demonstrated that CeO2 nanoparticles may be useful for the treatment of conditions associated with elevated oxidative stress including cardiac dysfunction, some types of neurodegeneration, cancer, and inflammation.7–10 Despite numerous medical advancements, the mortality rate associated with sepsis-associated multiple organ dysfunction syndrome remains unacceptably high as it is the leading cause of death in the hospital intensive care unit.11 Sepsis and other severe inflammatory disorders are often associated with diaphragm dysfunction, which if uncorrected oftentimes results in decreased survivability and the need for ventilator support.12–14
Recent work by our laboratory has suggested that treatment with CeO2 nanoparticles is associated with diminished sepsis-induced mortality and decreased levels of systemic inflammation after polymicrobial insult. Whether this increase in survivability following CeO2 nanoparticle intervention also associated with improvements of diaphragm function is currently unclear. On the basis of previous data demonstrating that rodent diaphragm is particularly susceptible to elevations in oxidative stress and circulating cytokines, we hypothesized that septic animals that had been treated with CeO2 nanoparticles would exhibit improved diaphragmatic function compared with that observed in the untreated counterparts. Our findings suggest that CeO2 nanoparticle treatment improves diaphragm contractility following a severe polymicrobial insult, and that this finding is associated with evidence of diminished muscle damage and inflammation.

Materials and methods

Materials

All chemicals were purchased from Sigma-Aldrich Co. (St Louis, MO, USA), unless otherwise specifically stated. Antibodies against Phospho-Akt (Ser473) (C31E5E) (#4060), Akt (pan) (40D4) (#2920), Phospho-Stat3 (Tyr705) (D3A7) XP (#9145), Stat3 (#9132), α-tubulin (#2144), Bax (#2772), Bcl-2 (#2876), Ubiquitin (p4D1) (#3936), 4E-BP1 phospho(thr37/46) (#9459), and 4E-BP1 Non phos (thr46) (#4923) were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated anti-mouse (#7076) and anti-rabbit (#7074) secondary antibodies were also purchased from Cell Signaling Technology. Caspase 8 primary antibody (sc-7890) was obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). iNOS primary antibody (PA1-036) was from Pierce (Rockford, IL, USA).

Animals

Ten-week-old male Sprague Dawley rats were purchased from Hilltop Laboratories (Scottdale, PA, USA) and housed for 1–2 weeks to allow acclimation before the initiation of any experiments. Animals were housed two to a cage with 12–12 dark–light cycles at 25°C. Food and water were provided ad libitum. All animal care and experimental procedures were performed after approval by the Marshall University Institutional Animal Care and Use Committee, and in accordance with the Guide for the Care and Use of Laboratory Animals.

Cecal inoculum peritonitis model

Animals were anesthetized using isoflurane and fecal peritonitis was induced by making a small abdominal incision followed by the introduction of cecal material and closure of the incision as described previously. The cecal material was prepared by mixing cecal contents obtained from fresh donor rats with 5% dextrose water to yield a concentration of 600 mg cecal material in 5 mL/kg. The cecal material was used immediately and prepared fresh for each experiment. The cecal inoculums (Cl) and Cl+CeO2 nanoparticle treatment animals received fresh inoculum from the same donor animal for each experiment. Sham control and CeO2-only animals underwent an identical surgery to induce fecal peritonitis but received sterile dextrose water (5 mL/kg, ip) only.

CeO2 nanoparticle treatment

The characterization of CeO2 nanoparticles (US Research Nanomaterials, Inc., Houston, TX, USA) were imaged using a JEOL JEM-2010 (JEOL, Tokyo, Japan) transmission electron microscope as previously described. Scanning transmission electron microscopy images were acquired using an aberration-corrected analytical electron microscope (transmission electron microscope [TEM]/scanning transmission electron microscope [STEM] JEOL JEM-ARM200CF) operated at 200 keV.

For the nanoparticle treatment groups, CeO2 nanoparticles (0.5 mg/kg) in 200 µL of sterile distilled water were given via the tail vein at the time of peritonitis induction or sham surgery. This dose was chosen based on our preliminary data from pilot studies examining animal mortality and previously published data. The sham control and the CI groups received vehicle (200 µL of sterile distilled water). For the biochemical assessments, animals were sacrificed at 3 or 18 hours while functional assessments of diaphragm contractility were performed at 18 hours. These time points were selected based on previous data suggesting that the 3-hour time point appears to represent the initial systemic inflammatory response syndrome phase while the 18-hour time point coincides with the development of multiple organ dysfunction.

In vitro diaphragm contraction

Diaphragm contractile function was measured as previously described. Briefly, the entire diaphragm with ribs and the central tendon attached was removed from isoflurane anesthetized animals and quickly placed in ice cold Krebs buffer solution containing (mM) 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 10 glucose, 1.2 NaH2PO4, and 25 NaHCO3 oxygenated with 95% O2 plus 5% CO2 to maintain pH 7.4. Two rectangular muscle strips approximately 3–4 mm in width from the costal region of each hemidiaphragm were dissected from the central tendon to the rib along the fiber orientation.
The central tendon and ribs were tied with silk sutures with loops to mount the muscle strips in the organ bath. The muscle strips were mounted on the two stainless pins in a glass organ bath, and electrical field stimulation (EFS) was delivered using two platinum electrodes along either side of the muscle (Grass Stimulator S88). The Krebs buffer solution in the organ bath contained 10 μM d-tubocurarine chloride (Sigma-Aldrich Co.) to block nicotinic acetylcholine receptors during electric stimulations, and the bath temperature was kept at 25°C. After the 15-minute equilibration, EFS with 2 milliseconds single square-wave pulse was delivered at super maximal voltage set at 140 V to contract the muscle strips. To determine optimal tension (L_{o}), diaphragm muscle strips were stretched in a stepwise manner, and the single-pulse twitch protocol was repeated to achieve the maximum active tension. Thereafter, tetanic tension was assessed at L_{o} by measuring active tension developed in response to the sequential stimulation with trains of 1–150 Hz stimuli (train duration 500 milliseconds). An interval of 3 minutes was used between the muscle contractions. Isometric contraction was recorded using a force displacement transducer (Grass Technologies, Warwick, RI) interfaced with a Grass polygraph, and the data were digitized at 5 kHz using a storage oscilloscope (DSO-8502, Link Instrument Inc., Fairfield, NJ, USA). Specific tension was normalized to the estimated muscle cross-sectional area by the following equation:

\[
\text{Cross sectional area} = \frac{\text{wet weight (g)/length (cm)}}{1.06 \text{ (density g/cm}^3)\text{)}^{25.}
\]

**Immunoblot analysis**

Semi-quantitative immunodetection was performed as detailed previously. Briefly, diaphragms were pulverized and then homogenized in Tissue Protein Extraction Reagent (Pierce) supplemented with 1 mM Dithiothreitol (DTT), protease, and phosphatase inhibitor cocktails (Sigma-Aldrich Co.). Lysates were sonicated on ice and centrifuged at 10,000 x g at 4°C for 10 minutes. The supernatant was removed, and protein concentration was determined by 660 protein assay reagent (Thermo Fisher Scientific, Waltham, MA, USA). Samples were diluted in Laemmli sample buffer, and equal amounts of protein were separated by SDS-PAGE, followed by electroblotting onto nitrocellulose membranes. Membranes were blocked with 5% milk in Tris Buffered Saline with Tween (TBST) for 1 hour at room temperature and washed three times in TBST before incubation overnight at 4°C with primary antibodies. Membranes were incubated with the secondary antibody conjugated with horseradish peroxidase (HRP) for 1 hour at room temperature. An enhanced chemiluminescence (ECL) was used to detect immunoreactivity using a FluorChem E System (Cell Biosciences, Santa Clara, CA, USA).

**Histochemical analysis**

**Procion orange**

A bolus administration of 1.5 mL (3% Procion orange in 0.9% sterile saline) was infused via femoral vein catheter. After allowing the dye to circulate for 15 minutes, the diaphragm muscle was removed and quickly frozen in liquid nitrogen-cooled isopentane. In some animals, muscle strips were immersed in HEPES buffer containing 0.2% Procion orange (Sigma-Aldrich Co.) for 1 hour at room temperature and quickly frozen as described above. Frozen tissues were serially sectioned in 10 μm and placed on poly-lysine-coated slides before imaging with an inverted fluorescent microscope (EVOS AMG, Bothell, WA, USA) under a green fluorescent protein filter (excitation 450 nm/emission 505 nm).

**Hematoxylin and eosin staining**

Frozen tissue sections from animals without Procion orange perfusion were fixed in 4% formalin in phosphate buffer solution (PBS), and the sections were stained with H&E according to the manufacturer (BBC Biochemical, Mount Vernon, WA, USA). Images were obtained using an inverted microscope (EVOS AMG).

**Real-time polymerase chain reaction**

Real-time polymerase chain reaction (PCR) was performed for quantification of iNOS and GAPDH using a 7500 Real Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA) as described previously. Briefly, total RNA was extracted using Trizol reagent (Sigma-Aldrich Co.) according to the manufacturer’s guidelines, and cDNA was synthesized using 1 μg of RNA with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). SYBR green PCR amplification was performed with SensiMix™SYBR low-ROX kit (Bioline, London, UK) using the following primers: iNOS (NM_012611.3; 5′-GGG TTT CCC GTT GAT GAC C-3′ and 5′-GCA GGC ACA CGC AAT GAT GG-3′; product size 126 bp) and GAPDH (NM_017008.4; 5′-GTT ACC AGG GCT GCC TTC TC-3′ and 5′-GGG TTT CCC GTT GAC CAC-3′; product size 168 bp) according to the manufacturer’s guidelines. Each sample was analyzed in triplicate in 25 μL reactions. A nontemplate control was used as a negative control and included in all PCR reactions. Specific products were determined by the melting curve analysis as well as agarose gel electrophoresis using ethidium bromide. Expression levels between groups were compared using the relative comparison method (2^{−ΔΔCT}).
Statistics
Data are presented as the mean and standard error of the mean as described in the text and figure legends. Statistical comparisons were made using paired $t$-tests and one- or two-way ANOVA with Bonferroni post hoc tests as appropriate. A $P<0.05$ was considered as significant.

Results

CeO$_2$ nanoparticle characterization
Details regarding the characterization of CeO$_2$ nanoparticles used in this study have been previously published.$^{15}$ SEM and TEM analyses suggested that the particles were likely spherical in shape and $\sim$15–20 nm in diameter (Figure 1A and B).

CeO$_2$ nanoparticle treatment improves diaphragmatic function in the septic rat
There were significant differences in pre-/post-body weight and serum hematocrit levels for the CI and CI+CeO$_2$ groups but not for the sham and CeO$_2$-only treated animals at 18 hours after the surgery (Table 1). The muscle length at which maximal tension was developed ($L_o$) was not different between groups (Table 1). Muscle strips from all groups demonstrated frequency-dependent increased tension (Figure 2A). Peak twitch tension was 93%±5%, 68%±4%, and 82%±5% of sham control for CeO$_2$ only, CI, and CI+CeO$_2$, respectively (Table 1; $P<0.05$). Similarly, peak tetanic tension was 89%±3%, 62%±4%, and 78%±4% of sham control for CeO$_2$ only, CI, and CI+CeO$_2$, respectively (Figure 2B; $P<0.05$). Consistent with these data, sepsis appeared to increase Procion orange dye diffusion into the diaphragm compared with that observed in the other groups (Figure 3A). Histological analysis following H&E staining suggested that sepsis was associated with increased cell infiltration that appeared to be diminished with nanoparticle treatment (Figure 3B).

CeO$_2$ nanoparticle treatment attenuates sepsis-associated diaphragm inflammatory
Nanoparticle treatment decreased sepsis-induced increases in Stat3 phosphorylation at 3- but not 18 hours (Figure 4A; $P<0.05$). Nanoparticle treatment significantly decreased $iNOS$ transcript levels and protein in the septic animals (Figure 4B and C; $P<0.05$).

CeO$_2$ nanoparticle treatment suppresses translation-related signaling, caspase 8 cleavage, and protein ubiquination during sepsis
Compared with the control animals, the phosphorylation of Akt, FOXO-1, and 4EBP-1 was not changed at 3 hours (data not shown). Nanoparticle treatment attenuated sepsis-induced decreases in the phosphorylation of Akt, FOXO-1, and 4EBP-1 at 18 hours (Figure 5A–C; $P<0.05$). Similarly, nanoparticle treatment reduced sepsis-associated protein ubiquination at 3 hours (Figure 6A; $P<0.05$) and caspase 8 cleavage at 18 hours (Figure 6B; $P<0.05$). Neither sepsis nor nanoparticle treatment was associated with changes in caspase 3 cleavage, apoptosis-inducing factor, or the ratio of Bax/Bcl-2 (data not shown).

Discussion
Previous work from our laboratory using the CI peritonitis model has demonstrated that CeO$_2$ nanoparticle treatment was associated with improved animal survivability and

![Figure 1](https://example.com/figure1.png)

**Figure 1** Characteristics of cerium oxide (CeO$_2$) nanoparticles.
**Notes:** Image of CeO$_2$ nanoparticle powder under transmission electron microscopy is shown (A, scale bar =1 µm). CeO$_2$ nanoparticles are further characterized by scanning electron microscopy (B, scale bar =20 nm).
diminished systemic inflammation\(^{15}\) with the latter occurring most likely due to diminished Kupffer cell activation.\(^{21}\) In this study, we show that CeO\(_2\) nanoparticle treatment attenuates the diaphragm dysfunction induced by the septic condition. We believe that these are the first data to demonstrate that nanoparticle treatments designed to target the liver Kupffer cells might be useful for preventing the muscle dysfunction and atrophy seen in clinical conditions characterized by severe systemic inflammation. Similar to earlier studies employing other sepsis models,\(^{23,29–31}\) we show that the CI

Table 1 Characteristics of diaphragm strip and animal each group at 18 hours

|                         | Sham control | CeO\(_2\) only | CI                 | CI+CeO\(_2\)         |
|-------------------------|--------------|----------------|--------------------|----------------------|
| Pre-body weight (g)     | 419.3±1.9    | 417.9±8.7      | 407.3±5.0          | 409.6±2.8            |
| Post-body weight (g)    | 425.3±2.1    | 420.8±8.2      | 396.1±4.5\(^{**}\) | 402.1±3.5\(^*\)      |
| Delta body weight (g)   | 6.1±1.2      | 2.9±1.5        | -10.0±1.3\(^*\)    | -7.6±2.2\(^*\)       |
| Hematocrit (%)          | 41.3±4.3     | 46.0±4.0       | 61.8±3.3\(^*\)     | 58.6±1.6\(^*\)       |
| Strip weight (mg)       | 39.7±3.7     | 36.2±2.8       | 39.7±1.7           | 39.3±1.9             |
| \(L_o\) (mm)            | 20.5±0.4     | 20.4±0.8       | 20.0±0.5           | 19.3±0.3             |
| \(P_t\) (N/cm\(^2\))    | 9.68±0.78    | 9.04±0.49      | 6.56±0.34\(^*\)    | 7.91±0.48            |
| \(P_o\) (N/cm\(^2\))    | 26.45±1.32   | 23.68±0.80     | 16.41±1.03\(^*\)   | 20.06±1.14\(^**\)    |
| Contraction time (ms)   | 51.28±2.74   | 55.53±3.82     | 49.22±1.74         | 48.19±2.36           |
| Half relaxation time (ms)| 50.45±4.00   | 57.87±4.58     | 58.65±5.27         | 50.00±3.14           |

Notes: \(^*\)P<0.05 compared with control group. \(^{**}\)P<0.05 compared with CI group by one-way ANOVA.

Abbreviations: CeO\(_2\), cerium oxide; CI, cecal inoculum; \(L_o\), optimal length; \(P_t\), maximal tetanic force; \(P_o\), maximal tetanic force.

Figure 2 Cerium oxide (CeO\(_2\)) nanoparticle treatment improves diaphragm contractility in cecal inoculum (CI) rat. Notes: Representative recording traces of contractile response are shown from each group (A). Group data showed that nanoparticle treatment improves diaphragm tension development (B, control n=8 strips from 4 rats, CeO\(_2\) only n=6 strips from 3 rats, cecal inoculum (CI) n=16 strips from 8 rats and CI+CeO\(_2\) n=18 strips from 9 rats). \(^{*}\)vs Control, \(^{*}\)vs CI: P<0.05 by two-way repeated measures ANOVA.
peritonitis model is also characterized by alterations in diaphragmatic function (Figure 2). Importantly, we also found that the CeO$_2$ nanoparticle treatment appeared to diminish the effects that the septic condition had on diaphragm tension development.

Whether these improvements in diaphragm contractility also reflect an improved pulmonary function in vivo is currently unclear. Similarly, why muscle function may be decreased with sepsis, or other conditions that are characterized by increased systemic inflammation are not entirely understood; however, it has been suggested that increased cellular infiltration and/or muscle membrane damage may play a role. To investigate this possibility, we examined the effects of sepsis and nanoparticle treatment on muscle histology and membrane permeability following exposure to Procion dye. Similar to previous reports, we found that the diaphragms obtained from septic animals exhibited a marked increase sarcolemma damage and cellular infiltration (Figure 3A). In addition, and consistent with our findings of improved contractile function with nanoparticle treatment, we found that these changes in cellular structure appeared to be lessened with nanoparticle treatment (Figure 3B). To extend these data, we next examined if the nanoparticle treatment modulated inflammatory signaling in diaphragm.

Several studies have suggested that elevations in the local (muscle) or circulating tumor necrosis factor (TNF)-alpha may play a key role in regulating diaphragmatic function during infection. Our data are consistent with this view and previous work from our laboratory that demonstrated elevations in systemic inflammation in the rat CI peritonitis model. How circulating cytokines cause muscle contractile dysfunction remains unclear; however, it has been shown that the activation of Stat3–iNOS signaling by elevations in IL-6 is associated with diminished cardiac

**Figure 3** Cerium oxide (CeO$_2$) nanoparticle treatment decreases cecal inoculum (CI) induced muscle damage.

**Notes:** Nanoparticle treatment functions to protect the muscle membrane as suggested by diminished Procion orange signal in the treated animals. Images were obtained using an inverted fluorescent microscope with 10× objective lens using a GFP filter (A). Sepsis increases and nanoparticle treatment decreases cellular infiltration. Representative bright field images were captured at 20× objective lens (B).

**Abbreviations:** GFP, green fluorescent protein; H&E, hematoxylin and eosin.
cerium oxide (CeO$_2$) nanoparticle treatment attenuates diaphragmatic inflammation after septic insult.

Notes: Cecal inoculum (CI) induced increases in Stat3 phosphorylation are diminished with nanoparticle treatment (A, n=6 rats/each group). Real-time PCR showed that iNOS gene expression levels was increased with CI group and diminished with nanoparticle treatment at 18 hours (B, n=6 rats/each group). Immunoblot for iNOS/α-tubulin is shown (C). *vs Control, **vs CI: P<0.05 by one-way ANOVA.

Abbreviation: PCR, polymerase chain reaction.

Figure 4 Cerium oxide (CeO$_2$) nanoparticle treatment attenuates diaphragmatic inflammation after septic insult.

Similar to the mechanisms of the inflammatory response in cardiac muscle, we found that sepsis significantly increased Stat3 phosphorylation in diaphragm, and importantly, that this increase was attenuated with nanoparticle treatment (Figure 4A). Likewise, increases in NO have been shown to directly impair contractile function in a number of different skeletal muscles including the diaphragm. $^{23,30,32,39}$ Consistent with this premise, we found that sepsis significantly increased $iNOS$ gene expression and protein content in diaphragm (Figure 4B and C). Similar
Figure 5 Cerium oxide (CeO$_2$) nanoparticle treatment normalizes the disruption of protein synthesis signaling in cecal inoculum (CI) peritonitis diaphragm.

**Notes:** Effect of nanoparticle on protein synthesis signaling was determined by immunoblot. Nanoparticle treatment increases phospho-Akt (A), phospho-Foxo1 (B), and phospho-4E-BP1 (C) levels in the septic diaphragm (n=6 rats/each group). *vs Control: P<0.05 by one-way ANOVA. **vs CI: P<0.05 by t-test.

To our contractile measurements, these alterations in NO signaling were attenuated with nanoparticle treatment. Given that CeO$_2$ nanoparticles have been shown to possess not only redox modulation but also immunomodulation properties in vitro,$^7$,$^8$,$^{40}$ it is possible that our in vivo CeO$_2$ nanoparticle treatment effects may be involved in the regulation of immune function and NO-associated oxidative stress. Taken together, these data suggest that nanoparticle treatment attenuated peritonitis-induced diaphragm dysfunction and that this improvement in contractility may be associated with diminished inflammatory signaling.

**CeO$_2$ nanoparticle treatment improves protein degradation/synthesis signaling in the septic diaphragm**

In addition to muscle damage and increased inflammatory signaling, it is also thought that increases in protein degradation
Figure 6 Cerium oxide (CeO$_2$) nanoparticle treatment decreases protein ubiquitination and caspase 8 cleavage during sepsis. Notes: Effect of nanoparticle on protein synthesis signaling was determined by immunoblot. Sepsis and treatment associated changes in protein ubiquitination (A) and caspase 8 cleavage (B). n=6 rats/each group. *vs Control; **vs CI: P<0.05 by one-way ANOVA.
may also be associated with diminished contractile function.\textsuperscript{41} It is thought that protein degradation is controlled, at least in part, by the activity of the muscle E3 ligases, MURF-1 and MAFbx, which, in turn, are thought to be regulated by FOXO-1. The activity of FOXO-1 is controlled by its phosphorylation by Akt, with increased FOXO-1 phosphorylation causing a decrease in its transcriptional activity.\textsuperscript{42} We found that total FOXO-1 expression was increased in CI peritonitis groups (Figure 5B). This finding is in agreement with previous reports that suggested that both cecal ligation and puncture (CLP)- and lipopolysaccharide (LPS)-induced sepsis models are associated with increased skeletal muscle FOXO-1 mRNA\textsuperscript{43,44} and protein levels.\textsuperscript{45} Conversely, we noted that peritonitis was associated with diminished ratio of Akt and FOXO-1 phosphorylated (active)/total protein and that this ratio that appeared to be attenuated with the treatment (Figure 5A and B). These data are consistent with the possibility that the CeO\textsubscript{2} nanoparticle intervention might function to diminish the degree of sepsis-induced muscle breakdown. Why sepsis might increase total FOXO-1 expression is currently unclear, but it is possible that this change could be a compensatory mechanism to counteract sepsis-associated decreases in FOXO-1 activity. Further studies will be required to address the mechanism(s) responsible for this change, and perhaps, more importantly, the physiological relevance of why sepsis might affect FOXO-1 protein levels in skeletal muscle. In addition to its ability to protect the muscle against apoptosis and protein degradation, it is also known that septic insults cause decrease protein translation signaling.\textsuperscript{46,47} To investigate this possibility, we next determined the effect of sepsis and the nanoparticle intervention on the phosphorylation of 4EBP-1. It is thought that 4EBP-1 functions to inhibit translation by binding to the translation initiation factor eIF4E. Consistent with previous work from other groups showing both endotoxemia and polymicrobial sepsis models decrease phosphorylation of 4EBP-1 in rat skeletal muscle,\textsuperscript{46,47} we found that sepsis was associated with decreased phosphorylation of 4EBP-1 (Figure 5C). Importantly, we also found that the nanoparticle treatment normalized this decreased phosphorylation of 4EBP-1 in diaphragm.

Similar to that observed for the effects of protein degradation on muscle function, it is also thought that increased muscle apoptosis can also diminish muscle function. Similar to previous reports using the LPS endotoxemia model\textsuperscript{48} and other work from our laboratory examining the effects of sepsis on circulating cytokine levels,\textsuperscript{15} we also found that this model was associated with increased caspase-8 cleavage (Figure 6B). To determine whether increases in caspase-8 cleavage led to increased muscle apoptosis, we next examined if peritonitis was associated with increased cleavage of caspase-3. Unlike previous data showing that LPS challenge increased caspase-3 activity in the rat diaphragm, we failed to find any change caspase-3 cleavage or caspase-3 activity in CI peritonitis model (data not shown). Supporting these data, we also failed to find any change in the ratio of Bax/Bcl-2 or in the amount of Apoptosis inducing factor (AIF) protein. Why endotoxemia but not the sepsis induced by peritonitis may be associated with increased caspase-3 activation is currently unclear.

**Conclusion**

In conclusion, we have demonstrated that CeO\textsubscript{2} nanoparticle treatment attenuated diaphragm dysfunction in a laboratory rat model of sepsis. We believe that this may be the first study to demonstrate that the systemic delivery of nanoparticles can be used to improve muscle function in a preclinical animal model of sepsis. How the nanoparticle treatment improved diaphragm contractility is currently unclear and will require additional experimentation.

**Acknowledgments**

This work was supported by DOE (DE-SC0005162) to ERB. The authors would like to acknowledge Niraj Nepal and Geeta Nandyala for sample collection and their technical assistance. The abstract of this article was presented at the Experimental Biology 2015 as a poster presentation with interim findings. The poster’s abstract was published in FASEB journal. Asano et al (2015) Cerium oxide (CeO\textsubscript{2}) nanoparticle treatment ameliorates peritonitis induced diaphragm dysfunction. The actual article, however, has never been published.

**Disclosure**

The authors declare that there are no conflicts of interests regarding the publication of this article.

**References**

1. Das S, Dowding JM, Klump KE, McGinnis JF, Self W, Seal S. Cerium oxide nanoparticles: applications and prospects in nanomedicine. Nanomedicine. 2013;8(9):1483–1508.
2. Nicolini V, Gambuzzi E, Malavasi G, et al. Evidence of catalase mimetic activity in Ce(3+)/Ce(4+) doped bioactive glasses. J Phys Chem B. 2015; 119(10):4009–4019.
3. Babu KS, Anandkumar M, Tsai TY, Kao TH, Inbaraj BS, Chen BH. Cytotoxicity and antibacterial activity of gold-supported cerium oxide nanoparticles. Int J Nanomed. 2014;9:5515–5531.
4. Hirst SM, Karakoti A, Singh S, et al. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol. 2013;28(2):107–118.
5. Wang Q, Perez JM, Webster TJ. Inhibited growth of Pseudomonas aeruginosa by dextran- and polyacrylic acid-coated ceria nanoparticles. Int J Nanomed. 2013;8:3395–3399.
6. Wason MS, Zhao J. Cerium oxide nanoparticles: potential applications for cancer and other diseases. Am J Transl Res. 2013;5(2):126–131.
7. Alili L, Sack M, von Montfort C, et al. Downregulation of tumor growth and invasion by redox-active nanoparticles. Antioxid Redox Signal. 2013;19(8):765–778.
8. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. Small. 2009;5(24):2848–2856.
9. Kong L, Cai X, Zhou X, et al. Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol. Dis. 2011;42(3):514–523.
10. Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. Cardiovasc. Res. 2007;73(3):549–559.
11. Schoenberg MH, Weiss M, Radermacher P. Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch. Surg. 1998;383(1):44–48.
12. Aubier M, Trippenbach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol Respir Environ Exerc Physiol. 1981;51(2):499–508.
13. Hussain SN, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol. 1985;59(6):1802–1808.
14. Scharf SM, Bark H. Function of canine diaphragm with hypovolemic shock and beta-adrenergic blockade. J Appl Physiol Respir Environ Exerc Physiol. 1984;56(3):648–655.
15. Selvaraj V, Manne ND, Arvapalli R, et al. Effect of cerium oxide nanoparticles on sepsis induced mortality and NF-kappab signaling in cultured macrophages. Nanomedicine. 2015;10(8):1275–1288.
16. Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102(14):1690–1696.
17. Khawi FA, Reid MB. N-acetylcysteine depresses contracture function and inhibits fatigue of diaphragm in vitro. J Appl Physiol. 1994;77(1):317–324.
18. Shindoh C, Hida W, Ohkawara Y, et al. TNF-alpha mRNA expression in diaphragm muscle after endotoxin administration. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1690–1696.
19. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press; 2011.
20. Sharma AC, Motew SJ, Farias S, et al. Sepsis alters myocardial and plasma concentrations of endothelin and nitric oxide in rats. J Mol Cell Cardiol. 1997;29(5):1469–1477.
21. Selvaraj V, Nepal N, Rogers S, et al. Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles. Biomaterials. 2015;59:160–171.
22. Kolli MB, Manne ND, Para, et al. Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary hypertension. Biomaterials. 2014;35(37):9951–9962.
23. Krause KM, Moody MR, Andrade FH, et al. Peritonitis causes diaphragm weakness in rats. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1277–1282.
24. Nethery D, DiMarco A, Stefan D, Supinski G. Sepsis increases contraction-related generation of reactive oxygen species in the diaphragm. J Appl Physiol. 1999;87(4):1279–1286.
25. Close RJ. Dynamic properties of mammalian skeletal muscles. Physiol Rev. 1972;52(1):129–197.
26. Katta A, Thulluri S, Manne ND, et al. Overload induced heat shock proteins (HSPs), MAPK and miRNA (miR-1 and miR133a) response in insulin-resistant skeletal muscle. Cell Physiol Biochem. 2013;31(2–3):219–229.
27. Hayot M, Barreiro E, Perez A, Czaika G, Comtois AS, Grassino AE. Morphological and functional recovery from diaphragm injury: an in vivo rat diaphragm injury. J Appl Physiol. 2001;90(6):2269–2278.
28. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcomere from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90(8):3710–3714.
